Ricarda Rauschenberg1, Johannes Bruns2, Julia Brütting3, Dirk Daubner4, Fabian Lohaus5, Lisa Zimmer6, Andrea Forschner7, Daniel Zips8, Jessica C Hassel9, Carola Berking10, Katharina C Kaehler11, Jochen Utikal12, Ralf Gutzmer13, Patrik Terheyden14, Frank Meiss15, David Rafei-Shamsabadi15, Felix Kiecker16, Dirk Debus17, Evelyn Dabrowski18, Andreas Arnold19, Marlene Garzarolli1, Marvin Kuske1, Stefan Beissert1, Steffen Löck5, Jennifer Linn20, Esther G C Troost21, Friedegund Meier22. 1. Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 2. Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 3. Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 4. Institute of Neuroradiology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 5. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany. 6. Department of Dermatology, University Hospital, University Duisburg-Essen, Germany & German Cancer Consortium (DKTK), Heidelberg, Germany. 7. Skin Cancer Center, Department of Dermatology, University Hospital Tübingen, Tübingen, Germany. 8. Department of Radiation Oncology, Skin Cancer Center, CCC Tübingen-Stuttgart, University of Tübingen, Germany. 9. Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. 10. Skin Cancer Center, Department of Dermatology and Allergy, University Hospital Munich, Munich, Germany. 11. Skin Cancer Center, Department of Dermatology, University Hospital Kiel, Kiel, Germany. 12. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany. 13. Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany. 14. Skin Cancer Center, Department of Dermatology, University of Lübeck, Lübeck, Germany. 15. Skin Cancer Center, Department of Dermatology and Venereology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 16. Skin Cancer Center, Department of Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany. 17. Skin Cancer Center, Department of Dermatology, Paracelsus Medical University, General Hospital Nuremberg, Germany. 18. Skin Cancer Center, Department of Dermatology, Ludwigshafen Medical Center, Ludwigshafen, Germany. 19. Skin Cancer Center, Department of Dermatology, Universitätsmedizin Greifswald, Greifswald, Germany. 20. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 21. National Center for Tumor Diseases (NCT), Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany. 22. Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: Friedegund.Meier@uniklinikum-dresden.de.
Abstract
BACKGROUND: Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs) achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) in retrospective analyses. However, several aspects of this treatment strategy remain poorly understood. We report on the overall survival (OS) of patients with MBM treated with a combination of radiotherapy (RT) and ST as well as the impact of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)-V600 mutation (BRAFmut) status, types of RT and ST and their sequence. PATIENTS AND METHODS: Data of 208 patients treated with SRS or whole brain radiation therapy (WBRT) and either immunotherapy (IT) or targeted therapy (TT) within a 6-week interval to RT were analysed retrospectively. OS was calculated from RT to death or last follow-up. Univariate and multivariate Cox proportional hazard analyses were performed to determine prognostic features associated with OS. RESULTS: The median follow-up was 7.3 months. 139 patients received IT, 67 received TT and 2 received IT and TT within 6 weeks to RT (WBRT 45%; SRS 55%). One-year Kaplan-Meier OS rates were 69%, 65%, 33% and 18% (P < .001) for SRS with IT, SRS with TT, WBRT with IT and WBRT with TT, respectively. Patients with a BRAFmut receiving IT combined with RT experienced higher OS rates (88%, 65%, 50% and 18%). TT following RT or started before and continued thereafter was associated with improved median OS compared with TT solely before RT (12.2 [95% confidence interval {CI} 9.3-15.1]; 9.8 [95% CI 6.9-12.6] versus 5.1 [95% CI 2.7-7.5]; P = .03). CONCLUSION: SRS and IT achieved the highest OS rates. A BRAFmut appears to be a favourable prognostic factor for OS. For the combination of RT and TT, the sequence appears to be crucial. Combinations of WBRT and ST achieved unprecedentedly high OS rates and warrant further studies.
BACKGROUND: Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs) achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) in retrospective analyses. However, several aspects of this treatment strategy remain poorly understood. We report on the overall survival (OS) of patients with MBM treated with a combination of radiotherapy (RT) and ST as well as the impact of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)-V600 mutation (BRAFmut) status, types of RT and ST and their sequence. PATIENTS AND METHODS: Data of 208 patients treated with SRS or whole brain radiation therapy (WBRT) and either immunotherapy (IT) or targeted therapy (TT) within a 6-week interval to RT were analysed retrospectively. OS was calculated from RT to death or last follow-up. Univariate and multivariate Cox proportional hazard analyses were performed to determine prognostic features associated with OS. RESULTS: The median follow-up was 7.3 months. 139 patients received IT, 67 received TT and 2 received IT and TT within 6 weeks to RT (WBRT 45%; SRS 55%). One-year Kaplan-Meier OS rates were 69%, 65%, 33% and 18% (P < .001) for SRS with IT, SRS with TT, WBRT with IT and WBRT with TT, respectively. Patients with a BRAFmut receiving IT combined with RT experienced higher OS rates (88%, 65%, 50% and 18%). TT following RT or started before and continued thereafter was associated with improved median OS compared with TT solely before RT (12.2 [95% confidence interval {CI} 9.3-15.1]; 9.8 [95% CI 6.9-12.6] versus 5.1 [95% CI 2.7-7.5]; P = .03). CONCLUSION:SRS and IT achieved the highest OS rates. A BRAFmut appears to be a favourable prognostic factor for OS. For the combination of RT and TT, the sequence appears to be crucial. Combinations of WBRT and ST achieved unprecedentedly high OS rates and warrant further studies.
Authors: Yang Wang; Bin Lian; Lu Si; ZhiHong Chi; XiNan Sheng; Xuan Wang; LiLi Mao; BiXia Tang; SiMing Li; XieQiao Yan; Xue Bai; Li Zhou; ChuanLiang Cui; Jun Guo Journal: J Cancer Res Clin Oncol Date: 2021-02-21 Impact factor: 4.553
Authors: Filipe Martins; Luis Schiappacasse; Marc Levivier; Constantin Tuleasca; Michel A Cuendet; Veronica Aedo-Lopez; Bianca Gautron Moura; Krisztian Homicsko; Adrienne Bettini; Gregoire Berthod; Camille L Gérard; Alexandre Wicky; Jean Bourhis; Olivier Michielin Journal: J Neurooncol Date: 2019-12-14 Impact factor: 4.130
Authors: Maria-Lisa Wilhelm; Mark K H Chan; Benedikt Abel; Florian Cremers; Frank-Andre Siebert; Stefan Wurster; David Krug; Robert Wolff; Jürgen Dunst; Guido Hildebrandt; Achim Schweikard; Dirk Rades; Floris Ernst; Oliver Blanck Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621
Authors: Teresa Amaral; Felix Kiecker; Sarah Schaefer; Henner Stege; Katharina Kaehler; Patrick Terheyden; Anja Gesierich; Ralf Gutzmer; Sebastian Haferkamp; Jochen Uttikal; Carola Berking; David Rafei-Shamsabadi; Lydia Reinhardt; Friedegund Meier; Ante Karoglan; Christian Posch; Thilo Gambichler; Claudia Pfoehler; Kai Thoms; Julia Tietze; Dirk Debus; Rudolf Herbst; Steffen Emmert; Carmen Loquai; Jessica C Hassel; Frank Meiss; Thomas Tueting; Vanessa Heinrich; Thomas Eigentler; Claus Garbe; Lisa Zimmer Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751
Authors: Vera Petrova; Ihor Arkhypov; Rebekka Weber; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky Journal: Int J Mol Sci Date: 2020-03-30 Impact factor: 5.923
Authors: Jana Schaule; Stephanie G C Kroeze; Oliver Blanck; Susanne Stera; Klaus H Kahl; Falk Roeder; Stephanie E Combs; David Kaul; An Claes; Markus M Schymalla; Sonja Adebahr; Franziska Eckert; Fabian Lohaus; Nasrin Abbasi-Senger; Guido Henke; Marcella Szuecs; Michael Geier; Nora Sundahl; Daniel Buergy; Reinhard Dummer; Matthias Guckenberger Journal: Radiat Oncol Date: 2020-06-01 Impact factor: 3.481